B-cell receptor on HER2-reactive B lymphocytes (HER2-specific BCR)

The B-cell receptor (BCR) on HER2-reactive B lymphocytes is a specialized surface immunoglobulin that specifically recognizes and binds to the Human Epidermal Growth Factor Receptor 2 (HER2) protein. In the context of HER2-positive malignancies, such as certain breast and gastric cancers, these specific B cells play a crucial role in the anti-tumor immune response by differentiating into plasma cells that secrete endogenous anti-HER2 antibodies. These antibodies can mediate tumor cell destruction through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement activation. Therapeutically, this BCR is targeted primarily through active immunotherapy or cancer vaccines designed to engage and expand the population of HER2-reactive B cells. By presenting HER2-derived peptides or proteins to these receptors, clinicians aim to boost the patient's own immune system to provide a sustained, polyclonal antibody response against the tumor. Research also explores the use of these receptors as biomarkers for predicting response to HER2-targeted therapies or as targets for selective depletion in rare cases where anti-HER2 antibodies might contribute to paraneoplastic syndromes or other autoimmune-like pathologies.

Other names

HER2-specific B-cell receptorAnti-HER2 B-cell receptorSurface immunoglobulin on HER2-specific B cells

Drugs targeting this receptor typically act as antigens to stimulate the B-cell receptor, leading to the expansion of HER2-reactive B cells and the subsequent production of endogenous anti-HER2 antibodies. Alternatively, in experimental settings, synthetic antigens or chimeric molecules may be used to selectively bind and eliminate these B cells if they are contributing to pathology.